In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Changing evidentiary standards: growth of the IVD market and heightened evidence requirements

This article was originally published in Clinica

Executive Summary

The in vitro diagnostics (IVD) market is currently one of the fastest-growing areas of clinical medicine in the US, with an annual growth of approximately 7% since 2004, and a projected growth rate of 9-13% per year until 2012. Within the IVD market, molecular diagnostics is the fastest-growing sector, constituting a $1-2bn dollar industry with annual growth of 30-50% in recent years. IVD test costs can range from approximately $20 for simple blood tests to thousands of dollars for more complex and novel diagnostics, and prices are quickly rising, particularly in the molecular diagnostics industry. The trend towards value-based pricing for high-end technologies has increased the level of evidence necessary to attain optimal payments from managed care organisations. Payers are now paying close attention to the clinical and economic utility of new products (eg, how the test or diagnostic will impact treatment decisions and the overall impact of the test on a plan's budget) when evaluating them for coverage.

You may also be interested in...

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

EuroPCR: Medtronic's drug-coated balloon keeps rising

A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts